Nicaragua and Russia Join Efforts in the Fight Against Cancer
In recent years, Russia has intensified its biomedical research aimed at developing cancer therapies, especially through personalized vaccine platforms.
TL;DR
- Russia is developing personalized cancer vaccines based on mRNA technology.
- Institutions like Gamaleya Center and FMBA are working on treatments for colorectal cancer, melanoma, glioblastoma, and other solid tumors.
- These therapies are individualized, based on genetic analysis of a patient's tumor to target specific mutations.
- President Putin has indicated Russia is close to creating cancer vaccines and next-generation immunomodulatory drugs.
- Preclinical trials have shown promising results, including tumor growth suppression and metastasis prevention.
- Human clinical trials are expected to begin for various formulations, including those for aggressive brain and skin cancers.
- The estimated cost per dose for personalized vaccines is around 300,000 rubles ($2,800).
- Russian authorities anticipate these treatments could be covered by the public health system.
- Hundreds of patients have expressed interest in experimental programs, with tumor samples being collected for personalized vaccine design.
- Nicaragua will join international scientific cooperation efforts focused on cancer treatments developed in Russia.
- The first patients for a personalized colon cancer vaccine have been selected, with sample collection and individualized development underway.
- Approvals for therapeutic vaccines against glioblastoma and melanoma are anticipated in 2026.
- Globally, lung cancer remains the leading cause of cancer death, followed by colorectal, liver, and breast cancers.